文献速递神经骨肌MR

低剂量非罗莫司醇在三维MR神经成像中抑制血管并改善臂丛神经显示

Three-dimensional MR Neurography of the Brachial Plexus: Vascular Suppression with Low-dose Ferumoxytol.
PubMed 文献 · Radiology · 2022-12-13

前瞻性纳入12名无贫血志愿者,在输注标准治疗剂量25%的非罗莫司醇后30分钟行三维短tau反转恢复T2加权快速自旋回波臂丛神经MR神经成像。结果显示,使用非罗莫司醇后血管抑制充分的比例从0%升至98%,神经显示充分评估增加,神经-血管对比比从0.6升至7.6,运动伪影无显著变化。

要点

  • 低剂量非罗莫司醇可显著抑制血管信号,提高臂丛神经三维MR神经成像的神经显示。
  • 加用血流抑制技术并未进一步改善神经-血管对比比。
  • 运动伪影在使用非罗莫司醇前后无显著差异。

关键影像表现/征象

  • 使用非罗莫司醇后,血管抑制充分(评分3)的扫描比例从0%增加到98%(P < .001)。
  • 神经显示充分(评分1或2)的个体神经评估比例从4%-63%增加到36%-100%(P < .001-.010)。
  • 运动伪影(评分0或1)的比例从33%变为52%,差异无统计学意义(P = .212)。
  • 定量神经-血管对比比从0.6(未使用)增加到7.6(使用非罗莫司醇)(P < .001)。
  • 使用非罗莫司醇后,加用血流抑制技术未改变神经-血管对比比(从7.5到8.4,P > .99)。

诊断标准与关键数值

  • 血管抑制程度采用0-3分定性评分(0为无抑制,3为完全抑制),充分抑制定义为评分3。
  • 神经可视化采用0-2分定性评分(0为无显示,2为完全显示),充分显示定义为评分1或2。
  • 运动伪影采用0-4分定性评分(0为无伪影,4为严重伪影),可接受定义为评分0或1。
  • 神经-血管对比比通过手动绘制感兴趣区计算。

临床应用与阅片要点

  • 低剂量非罗莫司醇(标准治疗剂量的25%)可有效抑制血管信号,有助于臂丛神经的显示。
  • 使用非罗莫司醇后,额外加用血流抑制技术可能不会进一步改善神经-血管对比。
  • 运动伪影在使用非罗莫司醇前后无显著变化,仍需注意控制运动。

局限性

  • 本研究为试点研究,样本量小(12名志愿者)。
  • 仅在无贫血志愿者中进行,未评估患者群体。
  • 单中心研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The efficacy of ferumoxytol, an ultrasmall superparamagnetic iron oxide particle for three-dimensional (3D) MR neurography, has yet to be evaluated. Purpose To evaluate the effects of low-dose ferumoxytol for vascular suppression and nerve visualization in 3D brachial plexus MR neurography as a pilot study. Materials and Methods Volunteers without anemia were prospectively enrolled in July 2021. Brachial plexus MR neurography was performed 30 minutes following infusion of 25% of the standard (510 mg of iron) therapeutic ferumoxytol dose with use of a 3D short-tau inversion recovery T2-weighted fast spin-echo sequence. The 3D fast spin-echo was acquired with and without the use of additional flow suppression techniques. Two musculoskeletal radiologists qualitatively evaluated examinations for the degree of vascular suppression (0-3, none to complete), nerve visualization (0-2, none to full), and motion artifact (0-4, none to severe). Nerve-to-fat, muscle, or vessel contrast ratios were calculated with use of manually drawn regions of interests. Comparisons of the proportion of scans with adequate image quality (vascular suppression, 3; nerve visualization, 1, 2; motion artifacts, 0, 1) were made with use of the McNemar test. Comparisons of quantitative contrast ratios were performed with use of Wilcoxon signed rank tests. P < .05 was deemed statistically significant. Results There were 12 volunteers (mean age, 25 years ± 3; six women) evaluated. The scans with adequate vascular suppression increased from 0% to 98% with and without ferumoxytol, respectively (P < .001). All individual nerve assessments of adequate nerve visualization increased from 4%-63% to 36%-100% without and with ferumoxytol, respectively (P < .001-.010), while motion artifacts were unchanged (from 33% to 52%, P = .212). Quantitatively, nerve-to-vessel contrast ratios increased from 0.6 without to 7.6 with ferumoxytol (P < .001). The addition of flow suppression did not change nerve-to-vessel contrast ratio quantitatively (from 7.5 to 8.4, P > .99) following ferumoxytol. Conclusion Low-dose ferumoxytol improved vascular suppression and nerve visualization in three-dimensional MR neurography of the brachial plexus compared to imaging without ferumoxytol. © RSNA, 2022.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Pedrick, Sneag, Colucci, et al. Three-dimensional MR Neurography of the Brachial Plexus: Vascular Suppression with Low-dose Ferumoxytol. Radiology. 2022. PMID: 36511805. doi:10.1148/radiol.221087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。